| Name | Title | Contact Details |
|---|---|---|
Masashi Shimazaki |
VP, Head of CI & Research Program Management in Oncology Research | Profile |
Wayne Berryman |
Assistant Director Information Security | Profile |
Anand Pattabiraman |
Senior Director of Information Systems | Profile |
Takeda Pharmaceuticals is a Wilmette, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Qualyst is a Durham, NC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Global Medical Institutes is a Princeton, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Trevi Therapeutics, Inc. is a late-stage clinical development company developing Nalbuphine® ER for chronic pruritus (itch). Pruritus develops in various dermatologic, metabolic, hematologic, and neuropathic conditions. The Company is pursuing two conditions for clinical development: uremic pruritus and prurigo nodularis. Uremic pruritus is a persistent and debilitating itch in patients on dialysis that has been associated with significant impairment in quality of life and increased mortality. Prurigo nodularis is an intensely pruritic dermatologic condition characterized by unsightly and itchy skin papules and nodules. There are no approved therapies in the United States or Europe for either condition.
Vista del Mar Hospital offers adolescent & adult inpatient psychiatric care, adult detox/dual diagnosis and partial hospitalization programs.